Interleukin-13 receptor subunit alpha-1 (IL13RA1) (IL13RA1)

Interleukin-13 receptor subunit alpha-1 (IL13RA1) is a transmembrane protein that serves as a primary binding component for the cytokine interleukin-13 (IL-13) [Source: UniProt P78552]. It functions by forming a heterodimeric complex with the interleukin-4 receptor alpha (IL4RA) chain, creating the Type II IL-4 receptor [Source: PubMed PMID: 10446104]. This complex is essential for mediating the effects of both IL-13 and IL-4 in non-hematopoietic cells, such as epithelial and smooth muscle cells [Source: PubMed PMID: 29307919]. Upon ligand binding, the receptor activates the JAK1/TYK2 and STAT6 signaling pathways, which are central to the pathogenesis of Type 2 inflammatory diseases [Source: PubMed PMID: 12486103]. IL13RA1 is heavily implicated in the development of asthma, atopic dermatitis, and eosinophilic esophagitis by promoting mucus production and tissue fibrosis [Source: PubMed PMID: 31141633]. Therapeutic agents targeting this pathway include monoclonal antibodies that either neutralize the IL-13 ligand or block the receptor subunits to prevent signal transduction [Source: PubMed PMID: 32534150]. Monitoring efficacy often involves measuring biomarkers like fractional exhaled nitric oxide (FeNO) and blood eosinophil counts [Source: PubMed PMID: 33743212].

Other names

CD213A1IL-13R-alpha-1IL-13RA1Interleukin-13 receptor alpha-1 chainCancer/testis antigen 110CT110NR4

Antagonism of the IL-13 signaling pathway by preventing the formation of the functional IL-13RA1/IL-4RA heterodimeric receptor complex, thereby inhibiting the activation of the JAK/STAT6 signaling cascade [Source: PubMed PMID: 29307919].